The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial
Abstract Alopecia areata (AA) is a recurrent chronic disease that affects hair follicles and results in hair loss. Make an increase in the number, thickness, and length of eyelashes is an important side effect of latanoprost eye drop. This study aimed to evaluate the effect of hypertrichosis property of latanoprost in the treatment of scalp AA. In this randomized double‐blind placebo‐controlled trial, 30 participants with scalp AA assigned to receive either topical latanoprost 0.005% solution or placebo for 12 weeks. In both arms, patients also received clobetasol 0.05% cream in isopropyl alcohol (1:1). The hair loss area pictured at baseline and the end of the fourth, eighth, and twelfth weeks. According to the images, the dermatologist assessed the hair loss area, hair density, and the severity of alopecia. Latanoprost significantly increased hair density (37.2 ± 26.1 vs. 14.6 ± 18.6) and regrowth (58.3 ± 39.3 vs. 21.6 ± 24.1) based on the Severity of Alopecia Tool (SALT) system compared to the control group ( p = 0.03 and 0.02, respectively). However, there were no significant differences between the two groups in reduction in the hair loss area and SALT, and the incidence of side effects ( p = 0.718, 0.262, and ≥0.99, respectively). Results showed the acceptable safety and efficacy of latanoprost 0.005% solution to increase hair density and regrowth. So, it could be safely used for the management of scalp AA..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Dermatologic Therapy - 35(2022), 6 |
| Beteiligte Personen: |
Rafati, Mohammadreza [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley Periodicals LLC. |
|---|
| Umfang: |
4 |
|---|
| doi: |
10.1111/dth.15450 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004679490 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004679490 | ||
| 003 | DE-627 | ||
| 005 | 20230307140726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/dth.15450 |2 doi | |
| 028 | 5 | 2 | |a DTH_DTH15450.xml |
| 035 | |a (DE-627)WLY004679490 | ||
| 035 | |a (WILEY)DTH15450 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.93 |2 bkl | ||
| 100 | 1 | |a Rafati, Mohammadreza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial |
| 264 | 1 | |c 2022 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Abstract Alopecia areata (AA) is a recurrent chronic disease that affects hair follicles and results in hair loss. Make an increase in the number, thickness, and length of eyelashes is an important side effect of latanoprost eye drop. This study aimed to evaluate the effect of hypertrichosis property of latanoprost in the treatment of scalp AA. In this randomized double‐blind placebo‐controlled trial, 30 participants with scalp AA assigned to receive either topical latanoprost 0.005% solution or placebo for 12 weeks. In both arms, patients also received clobetasol 0.05% cream in isopropyl alcohol (1:1). The hair loss area pictured at baseline and the end of the fourth, eighth, and twelfth weeks. According to the images, the dermatologist assessed the hair loss area, hair density, and the severity of alopecia. Latanoprost significantly increased hair density (37.2 ± 26.1 vs. 14.6 ± 18.6) and regrowth (58.3 ± 39.3 vs. 21.6 ± 24.1) based on the Severity of Alopecia Tool (SALT) system compared to the control group ( p = 0.03 and 0.02, respectively). However, there were no significant differences between the two groups in reduction in the hair loss area and SALT, and the incidence of side effects ( p = 0.718, 0.262, and ≥0.99, respectively). Results showed the acceptable safety and efficacy of latanoprost 0.005% solution to increase hair density and regrowth. So, it could be safely used for the management of scalp AA. | ||
| 700 | 1 | |a Mahmoudian, Reza |4 aut | |
| 700 | 1 | |a Golpour, Masoud |4 aut | |
| 700 | 1 | |a Kazeminejad, Armaghan |4 aut | |
| 700 | 1 | |a Saeedi, Majid |4 aut | |
| 700 | 1 | |a Nekoukar, Zahra |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologic Therapy |g 35(2022), 6 |w (DE-627)WLY00465188X |x 15298019 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:6 |g extent:4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.93 |q ASE |
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 6 |g 4 | ||